Migdal Insurance & Financial Holdings Ltd. Verona Pharma PLC Transaction History

Migdal Insurance & Financial Holdings Ltd.

$6.18 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 02, 2022	SELL	$4.82 - $6.98 $3,981 - $5,765	-826 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$3.91 - $7.08 $1,947 - $3,525	-498 Reduced 37.61%	826 $6,000
Q3 2021 Nov 16, 2021	BUY	$5.29 - $6.35 $7,003 - $8,407	1,324 New	1,324 $7,000

Others Institutions Holding VRNA

# of Institutions

167

Shares Held

68.7M

Call Options Held

704K

Put Options Held

685K

Perceptive Advisors LLC New York, NY

6.32M
Shares

$284 Million
4.75% of portfolio
Nea Management Company, LLC Timonium, MD

5.58M
Shares

$252 Million
12.27% of portfolio
Ra Capital Management, L.P. Boston, MA

5.01M
Shares

$226 Million
2.01% of portfolio
Lee Ainslie Maverick Capital LTD | Dallas, Tx

4.22M
Shares

$190 Million
2.52% of portfolio
Vivo Capital, LLC Palo Alto, CA

3.55M
Shares

$160 Million
14.95% of portfolio

View Full List

About Verona Pharma plc

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $2.75B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

More about VRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account